Eli Lilly And Co vs iShares Semiconductor ETF — how do they compare? Eli Lilly And Co trades at $1,163.89 (market cap $1.02T), while iShares Semiconductor ETF trades at $553.63. The key difference: Eli Lilly And Co pays a 0.6% dividend while iShares Semiconductor ETF pays none. Which is the better fit depends on your goals.
| LLY | SOXX | |
|---|---|---|
Market Cap | $1.02T | — |
Sector | Health | Sector/Thematic |
52-Week High | $1.24K | $655.01 |
52-Week Low | $625.65 | $236.93 |
Enterprise Value | $1.06T | — |
Dividend Yield | 0.6% | — |
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
SOXX, the iShares Semiconductor ETF, trades at $524.14, up 0.45% on the day but down 20% from its June 2026 all-time high, reflecting a sector-wide correction. Technical indicators are bearish, with the ETF facing resistance near $533. Recent news highlights a sharp pullback in semiconductor stocks amid concerns over AI-driven valuations and cyclical pressures, though long-term demand drivers remain intact.
The outlook for SOXX is cautious near-term due to technical weakness and sentiment headwinds, but the ETF's concentrated exposure to leading chipmakers offers growth potential if AI and memory demand persist. Key risks include sector volatility, valuation concerns, and macroeconomic shifts impacting tech spending.
Trailing returns across standard periods
Latest headlines on both assets
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →SOXX provides investors with exposure to U.S. companies that design, manufacture, and distribute semiconductors. It tracks the ICE Semiconductor Index, offering a targeted investment in the technology sector's foundational components, including firms that produce chips, related equipment, and services. SOXX is a key vehicle for investors seeking to capitalize on trends in artificial intelligence, 5G, and other technologies that rely heavily on advanced semiconductor technology.
Read more on SOXX →